

- 9 Janknegt RA, Chapple CR, for the Doxazosin study group: Efficacy and safety of the alpha 1-blocker doxazosin in the treatment of benign prostatic hyperplasia. Analysis of 5 studies. *Eur Urol* 1993;24:319–326.
- 10 Jardin A, Bensadoun H, DeLauche-Cavallier MC, et al: Alfuzosin for the treatment of benign prostatic hypertrophy. *Lancet* 1991;337:1457–1461.
- 11 Teillac P, Delauche Cavallier MC, Attali P and the DUALF Group: Urinary flow rates in patients with benign prostatic hypertrophy following treatment with alfuzosin. *Br J Urol* 1992;70:58–64.
- 12 Jardin A, Bensadoun H, Delauche Cavallier MC, et al: Long term treatment of benign prostatic hyperplasia with alfuzosin. A 24–30 month survey. *Br J Urol* 1994;74:579–584.
- 13 Buzeln JM, Roth S, Geffriaud-Ricouard C, Delauche-Cavallier MC and the ALGEBI study Group: Efficacy and safety of sustained-release alfuzosin 5 mg in patients with benign prostatic hyperplasia. *Eur Urol* 1997;21:190–198.
- 14 Buzeln JM, Herbert M, Blondin P and the PRAZALF group: Alpha-blocking treatment with alfuzosin in symptomatic benign prostatic hyperplasia: Comparative study with prazosin. *Br J Urol* 1993;72:922–927.
- 15 Abrams P, Buzeln JM, Griffiths D et al: The urodynamic assessment of lower urinary tract symptoms. *Proc 4th Int Consult Benign Prostatic Hyperplasia (BPH)*. Jersey, 1998, pp 323–377.
- 16 Rossi C, Kortmann BBM, Sonke GS, et al: Alpha-blockade improves symptoms suggestive of bladder outlet obstruction but fails to relieve it. *J Urol* 2001;165:38–41.
- 17 Martorana G, Giberti C, Di Silverio F, et al: Effect of short-term treatment with the alpha-1-blocker alfuzosin on urodynamic pressure-flow parameters in patients with benign prostatic hyperplasia. *Eur Urol* 1997;32:47–51.
- 18 Schäfer W: Analysis of bladder-outlet function with the linearized passive urethral resistance relation, linPURR, and a disease-specific approach for grading obstruction: From complex to simple. *World J Urol* 1995;13:47–58.
- 19 McNeill S, Hargreave TB, Geffriaud-Ricouard C, et al: Postvoid residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: Pooled analysis of eleven controlled studies with alfuzosin. *Urology* 2000;57:459–465.
- 20 Perlberg S, Caine M: Adrenergic response of bladder muscle in prostatic obstruction. *Urology* 1982;20:524–527.

Announcement

C.E. Alken Prize

Announcement and Rules

(1) The C.E. Alken Foundation supports clinical and experimental research through an annual prize for outstanding scientific work.

(2) The C.E. Alken Prize is awarded for the best unpublished scientific work in the field of urology and may be divided. The prize comprises a certificate and the sum of CHF 10,000.–.

(3) Manuscripts can be submitted in either English or German. Seven copies of the manuscript should be sent to the following address and marked for the attention of Mr. E. Hauser, Advocate:

C.E. Alken Foundation
Dr. F. Kellerhals & Partner
Marktgasse 55
CH–3011 Bern (Switzerland)

The deadline for submission of manuscripts is September 1, 2003. Each paper has to be marked with a code word and must not include the name of the author. An additional sealed envelope (marked on the outside with the code word) has to be enclosed and must contain the following:

- curriculum vitae of the author (maximum 3 pages)
- structured summary of the manuscript (aim of study, materials/methods, results, conclusions)

(4) The award winner will be determined by the Foundation Council, the decision of which is final.

C.E. Alken Foundation Council